SEC 13F Intelligence

Managers / Q2 2019 · view latest →

Consonance Capital Management LP

CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062

Reported Value
$1.4B
Q2 2019
Positions
30
Filings on Record
15
2019–present window
Filed
Aug 14, 2019
original filing

Summary

Consonance Capital Management LP reported $1.4B in U.S.-listed holdings across 30 positions for Q2 2019.

Its largest position, Amarin, represents 11.8% of the portfolio.

Compared with Q1 2019, the fund opened 7 new positions and exited 3.

Portfolio Metrics

Turnover
+20.8%
vs prior filed quarter
Top-10 Concentration
+67.5%
share of reported value
Largest Position
+11.8%
Amarin
New / Exited
7 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $1.6BQ1 ’19Q2 ’19: $1.4BQ3 ’19: $1.0BQ3 ’19Q4 ’19: $1.6BQ1 ’20: $1.3BQ1 ’20Q2 ’20: $1.7BQ3 ’20: $821MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $938MQ1 ’21Q2 ’21: $831MQ3 ’21: $183MQ3 ’21Q4 ’21: $153MQ1 ’22: $59MQ1 ’22Q2 ’22: $24MQ3 ’22: $7MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 85.9%Other: 14.1%
  • Common Stock · 85.9% · $1.2B
  • Other · 14.1% · $199M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
INSMINSMED INCNEW+1.71M1.71M+$44M$44M
INTERCEPT PHARMACEUTICALS INNEW+388.5K388.5K+$31M$31M
STAASTAAR SURGICAL CONEW+484.6K484.6K+$14M$14M
MUSTANG BIO INCNEW+3.38M3.38M+$12M$12M
KRYSKRYSTAL BIOTECH INCNEW+182.1K182.1K+$7M$7M
ARQULE INCNEW+50.0K50.0K+$551,000$551,000
HOMOLOGY MEDICINES INCNEW+26.2K26.2K+$512,000$512,000
IOVAIOVANCE BIOTHERAPEUTICS INCADDED+4.71M5.85M+$133M$144M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2019

30 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1AMARIN CORP PLCSPONS ADR NEW11.82%$167M8.61M
2QUREUNIQURE NVhistory →SHS10.57%$149M1.91M
3IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM10.16%$144M5.85M
4PCRXPACIRA BIOSCIENCEShistory →COM8.62%$122M2.80M
5RETROPHIN INCCOM5.42%$77M3.81M
6CN2CATALYST PHARMACEUTICALS INChistory →COM4.86%$69M17.88M
7UTHRUNITED THERAPEUTICS CORP DELhistory →COM4.26%$60M770.8K
8EPIZYME INCCOM4.23%$60M4.76M
9VCELVERICEL CORPhistory →COM3.92%$55M2.93M
10URGNUROGEN PHARMA LTDhistory →COM3.65%$52M1.43M
11VNDAVANDA PHARMACEUTICALS INChistory →COM3.62%$51M3.63M
12OMEROMEROS CORPhistory →COM3.39%$48M3.05M
13AERIE PHARMACEUTICALS INCCOM3.15%$45M1.51M
14INSMINSMED INChistory →COM PAR $.013.10%$44M1.71M
15KARYOPHARM THERAPEUTICS INCCOM2.46%$35M5.80M
16OXFORD IMMUNOTEC GLOBAL PLCORD SHS2.28%$32M2.34M
17CORTCORCEPT THERAPEUTICS INChistory →COM2.27%$32M2.88M
18INTERCEPT PHARMACEUTICALS INCOM2.19%$31M388.5K
19AUPHAURINIA PHARMACEUTICALS INChistory →COM1.97%$28M4.22M
20KDMNKADMON HLDGS INChistory →COM1.70%$24M11.63M
21ADMAADMA BIOLOGICS INChistory →COM1.56%$22M5.71M
22CHEMOCENTRYX INCCOM1.10%$16M1.67M
23STAASTAAR SURGICAL COhistory →COM PAR $0.011.01%$14M484.6K
24MUSTANG BIO INCCOM0.88%$12M3.38M
25ANIPANI PHARMACEUTICALS INChistory →COM0.83%$12M142.9K
26KRYSKRYSTAL BIOTECH INCCOM0.52%$7M182.1K
27SVRASAVARA INCCOM0.26%$4M1.57M
28IMMUIMMUNOMEDICS INCCOM0.14%$2M145.0K
29ARQULE INCCOM0.04%$551,00050.0K
30HOMOLOGY MEDICINES INCCOM0.04%$512,00026.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$7M2Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$24M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M8May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$153M15Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$183M17Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$831M32Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$938M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.1B38Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$821M27Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.3B31May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.6B35Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.0B30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.4B30Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.6B26May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.